Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Synaptic loss underlies the memory deficit of Alzheimer's disease (AD). The molecular mechanism is elusive; however, excitatory synapses organized by the postsynaptic density (PSD) have been used as targets for AD treatment. To identify pathological entities at the synapse in AD, synaptic proteins were screened by quantitative proteomic profiling. The critical proteins were then selected for immunoblot analysis. The glutamate receptors N-methyl-d-aspartate (NMDA) receptor 1 and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 2 (GluR2) were substantially lost; specifically, the loss of GluR2 was up to 40% at PSD in AD. Shank proteins, the organizers of these glutamate receptors at excitatory synapses, were dramatically altered in AD. The level of Shank2 was increased, whereas the protein level of Shank3 was decreased. Further, the Shank3 protein was modified by ubiquitin, indicating that abnormal activity of the ubiquitin–proteasome system may lead to Shank3 degradation in AD. Our findings suggest that disruption of glutamate receptors at the Shank-postsynaptic platform could contribute to destruction of the PSD which underlies the synaptic dysfunction and loss in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“The pathological lesion of AD includes three hallmark changes: amyloid plaques, neurofibrillary tangles and synaptic loss (Haass and Selkoe, 2007).”
BackgroundAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 2×
“…system; IRSp53, insulin receptor substrate . level (Thorns et al., 1997), gene expression (Hynd et al., 2003), channel activity (Shemer et al., 2006), and trafficking (Snyder et al., 2005) in vivo and in vitro from human AD postmortem tissue, transgenic AD mouse models and neuronal culture.”
BackgroundGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 2×
“Western analysis was based on published procedures (Gong et al., 2003).”
BackgroundMethodSelf-citationThe Postsynaptic Architecture of Excitatory Synapses: A More Quantitative View
Sheng, M., & Hoogenraad, C. C. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060805.160029 · Cited by 1,003
Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system
Ehlers, M. D. (2003) · Nature Neuroscience · doi:10.1038/nn1013 · Cited by 977
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Self-citationKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Hung, A. Y., Futai, K., Sala, C., Valtschanoff, J. G., Ryu, J., Woodworth, M. A., Kidd, F. L., Sung, C. C., Miyakawa, T., Bear, M. F., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3032-07.2008 · Cited by 350
Shank Expression Is Sufficient to Induce Functional Dendritic Spine Synapses in Aspiny Neurons
Roussignol, G., Ango, F., Romorini, S., Tu, J. C., Sala, C., Worley, P. F., Bockaert, J., & Fagni, L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4354-04.2005 · Cited by 293
An Architectural Framework That May Lie at the Core of the Postsynaptic Density
Baron, M. K., Boeckers, T. M., Vaida, B., Faham, S., Gingery, M., Sawaya, M. R., Salyer, D., Gundelfinger, E. D., & Bowie, J. U. (2006) · Science · doi:10.1126/science.1118995 · Cited by 292 · cited 3×
“We found that Shank proteins, forming postsynaptic platform to integrate subunits of glutamate receptor on the postsynaptic membrane and to organize the PSD structure and to maintain synaptic function (Baron et al., 2006), were dramatically altered in AD.”
BackgroundSynaptic Changes in Alzheimer's Disease
Gylys, K. H., Fein, J. A., Yang, F., Wiley, D. J., Miller, C. A., & Cole, G. M. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63436-0 · Cited by 253
AMPA potentiator treatment of cognitive deficits in Alzheimer disease
Chappell, A. S., Gonzales, C., Williams, J., Witte, M. M., Mohs, R. C., & Sperling, R. (2007) · Neurology · doi:10.1212/01.wnl.0000260240.46070.7c · Cited by 89 · cited 1×
“The use of NMDA receptor and other glutamate receptors, such as AMPA, as targets for AD clinical treatment (Robinson and Keating, 2006) or in clinical trials (Chappell et al., 2007) further supports this.”
Background
Cited by
Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., & Wang, Q. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.02.002 · Cited by 301
Loss of functional GABA A receptors in the Alzheimer diseased brain
Limon, A., Reyes-Ruiz, J. M., & Miledi, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204606109 · Cited by 264
The emerging role of SHANK genes in neuropsychiatric disorders
Guilmatre, A., Huguet, G., Delorme, R., & Bourgeron, T. (2014) · Developmental Neurobiology · doi:10.1002/dneu.22128 · Cited by 237
Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies
Grabrucker, A. M., Schmeisser, M. J., Schoen, M., & Boeckers, T. M. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.07.003 · Cited by 233
Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation
Grabrucker, A. M., Knight, M. J., Proepper, C., Bockmann, J., Joubert, M., Rowan, M., Nienhaus, G. U., Garner, C. C., Bowie, J. U., Kreutz, M. R., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.336 · Cited by 228
Metadata
- Authors
- Gong, Y., Lippa, C. F., Zhu, J., Lin, Q., & Rosso, A. L.
- Venue
- Brain Research
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 1292
- Pages
- 191-198
- ISSN
- 0006-8993 (ISSN-L)
- OpenAlex
- W2149214914
- Cited by
- 98
- References
- 13
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.